コンテンツへスキップ
Merck
  • Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation.

Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation.

Clinical and experimental nephrology (2019-11-27)
Osamu Soma, Shingo Hatakeyama, Tohru Yoneyama, Mitsuru Saito, Hideo Sasaki, Yuki Tobisawa, Daisuke Noro, Yuichiro Suzuki, Masakazu Tanaka, Shin-Ichiro Nishimura, Hiroshi Harada, Hideki Ishida, Kazunari Tanabe, Shigeru Satoh, Chikara Ohyama
要旨

To evaluate whether serum N-glycan profile can be used as a diagnostic marker of graft rejection after living-donor kidney transplants (KT). We retrospectively examined 174 KT recipients at five medical centers. N-Glycan levels were analyzed in postoperative serum samples using glycoblotting combined with mass spectrometry. We developed an integrated score to predict graft rejection based on a combination of age, gender, immunological risk factors, and serum N-glycan levels at post-KT day D1 and D7. Rejection-free survival rates stratified by the sum of integrated scores (D1 + D7) were evaluated using Kaplan-Meier curves. Of 174, 52 showed graft rejection (Rejection-pos. group) and 122 recipients did not show graft rejection (Rejection-neg. group). The integrated scores were significantly higher in the Rejection-pos. group than those of the Rejection-neg. group. Area-under-curve (AUC) value of integrated scores at post-KT D1, and D7 were 0.84 and 0.84, respectively. The sum of integrated scores (D1 + D7) ≥ 0.50 identified graft rejection with 81% sensitivity and 80% specificity; with an AUC value of 0.87. Recipients with higher sum of integrated scores (D1 + D7 ≥ 0.5) had significantly shorter rejection-free survival than those with lower scores. Evaluation of serum N-glycosylation profiles can identify recipients who are prone to rejection.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
O-ベンジルヒドロキシルアミン, AldrichCPR